Terms: = Bone cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
163 results:
1. [Recurrent Breast cancer with bone Metastasis Effectively Treated with Abemaciclib plus Endocrine Therapy-A Case Report].
Adachi K; Nagae J; Kubota H; Suzuki S; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1845-1847. PubMed ID: 38303227
[TBL] [Abstract] [Full Text] [Related]
2. [bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation in a Breast cancer Patient Treated with Chemotherapy and cdk4/6 Inhibitor].
Kume S; Makino T; Goto A; Onodera Y; Kudo S
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1331-1333. PubMed ID: 38247075
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
4. Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.
Genet G; Genet N; Paila U; Cain SR; Cwiek A; Chavkin NW; Serbulea V; Figueras A; Cerdà P; McDonnell SP; Sankaranarayanan D; Huba M; Nelson EA; Riera-Mestre A; Hirschi KK
Circulation; 2024 Mar; 149(12):944-962. PubMed ID: 38126211
[TBL] [Abstract] [Full Text] [Related]
5. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
6. Interstitial lung disease and cdk4/6 inhibitors in the treatment of breast cancer.
Schlam I; Giordano A; Tolaney SM
Expert Opin Drug Saf; 2023; 22(12):1149-1156. PubMed ID: 37994878
[TBL] [Abstract] [Full Text] [Related]
7. A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent cancer Cells.
Calvo V; Zheng W; Adam-Artigues A; Staschke KA; Huang X; Cheung JF; Nobre AR; Fujisawa S; Liu D; Fumagalli M; Surguladze D; Stokes ME; Nowacek A; Mulvihill M; Farias EF; Aguirre-Ghiso JA
Clin Cancer Res; 2023 Dec; 29(24):5155-5172. PubMed ID: 37982738
[TBL] [Abstract] [Full Text] [Related]
8. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract] [Full Text] [Related]
9. A new perspective on the proper timing of radiotherapy during cdk4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer.
Tornyi I; Árkosy P; Horváth I; Furka A
Pathol Oncol Res; 2023; 29():1611369. PubMed ID: 37886029
[TBL] [Abstract] [Full Text] [Related]
10. The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications.
Denu RA; Moyers JT; Gouda MA; Conley AP; Lazar AJ; Subbiah V
Clin Cancer Res; 2023 Nov; 29(22):4669-4678. PubMed ID: 37643131
[TBL] [Abstract] [Full Text] [Related]
11. KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated Sarcoma.
Motoi T; Hirata M; Kukita Y; Satomi K; Tamura H; Adachi S; Matsushita Y; Horiguchi SI; Hishima T; Ikegami M; Okuma T; Tao K; Arakawa A; Ogawa C; Matsuda K; Ichimura K; Nakamura H; Mori T; Yoshida A
Mod Pathol; 2023 Nov; 36(11):100317. PubMed ID: 37634866
[TBL] [Abstract] [Full Text] [Related]
12. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
13. cdk4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract] [Full Text] [Related]
14. Successful continuance of cdk4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Ozawa Y; Fujimiya T; Shimada A; Okazawa A; Kusano J; Yamamoto R; Hyasashi S
Anticancer Drugs; 2024 Jan; 35(1):89-92. PubMed ID: 37578747
[TBL] [Abstract] [Full Text] [Related]
15. Gastric and bone Metastases Arising from Invasive Lobular Carcinoma With Ductal Carcinoma Occurring in one Breast Synchronously.
Namikawa T; Yokota K; Maeda H; Kitagawa H; Tamura M; Satake H; Sugimoto T; Kobayashi M; Hanazaki K; Seo S
Anticancer Res; 2023 Aug; 43(8):3701-3707. PubMed ID: 37500131
[TBL] [Abstract] [Full Text] [Related]
16. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
17. Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Bender L; Pflumio C; Trensz P; Pierard L; Kalish M; Fischbach C; Petit T
Cancer Treat Res Commun; 2023; 36():100738. PubMed ID: 37390791
[TBL] [Abstract] [Full Text] [Related]
18. Impact of cdk4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.
Skafida E; Andrikopoulou A; Terpos E; Markellos C; Moustafa S; Pectasides D; Dimopoulos MA; Zagouri F; Vassilopoulos D
Breast J; 2023; 2023():3614296. PubMed ID: 37293258
[TBL] [Abstract] [Full Text] [Related]
19. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P; Zhang Q; Tong Z; Sun T; Li W; Ouyang Q; Hu X; Cheng Y; Yan M; Pan Y; Teng Y; Yan X; Wang Y; Xie W; Zeng X; Wang X; Hu C; Geng C; Zhang H; Li W; Wu X; Zhong J; Xu J; Shi Y; Wei W; Bayaxi N; Zhu X; Xu B
Lancet Oncol; 2023 Jun; 24(6):646-657. PubMed ID: 37182538
[TBL] [Abstract] [Full Text] [Related]
20. Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
Bayram D; Aktürk Esen S; Uçar G; Köş FT
J Oncol Pharm Pract; 2023 Sep; 29(6):1494-1497. PubMed ID: 37170613
[TBL] [Abstract] [Full Text] [Related]
[Next]
